Immune checkpoints HLA-E:CD94-NKG2A and HLA-C:KIR2DL1 complementarily shield circulating tumor cells from NK-mediated immune surveillance

• Xiaowei Liu,
• Fengli Zuo,
• Jinen Song,
• Leyi Tang,
• Xueyan Wang,
• Xinyu Liu,
• Hao Zhang,
• Zhankun Yang,
• Jing Jing,
• Xuelei Ma,
• Hubing Shi

Affiliations

Xiaowei Liu

Institute for Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University

Fengli Zuo

Institute for Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University

Jinen Song

Institute for Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University

Leyi Tang

Institute for Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University

Xueyan Wang

Institute for Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University

Xinyu Liu

Institute for Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University

Hao Zhang

Department of Pancreatic Surgery, West China Hospital, Sichuan University

Zhankun Yang

College of Chemical Engineering, Shijiazhuang University

Jing Jing

Institute for Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University

Xuelei Ma

Department of Biotherapy, West China Hospital and State Key Laboratory of Biotherapy, Sichuan University

Hubing Shi

Institute for Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University